Jane Bayani

Abstract Approximately 80% of all breast cancer cases are estrogen receptor-positive (ER+). This subtype is known to have distant recurrences in a subset of patients after adjuvant endocrine therapy, partially due to the heterogeneity of the disease. ER+ breast cancer has been generally classified as an immune-cold disease. Thus, to better inform treatment decisions and to consider the prospect of immunotherapy, the immune microenvironment needs to be thoroughly characterized.

Inclusion and exclusion criteria Patients with suspected ILF after radiation will be recruited. Patients must have a BCF per Phoenix criteria at least two years after initial prostate cancer treatment, an intra-prostatic lesion with PSMA PET avidity (Standard Uptake Value (SUV) of 3.0 or greater on a diagnostic PSMA PET/CT), and no evidence of extra prostatic disease.

Loading metrics Open Access Peer-reviewed Research Article John M. S. Bartlett , Jane Bayani , Elizabeth N. Kornaga , Patrick Danaher, Cheryl Crozier, Tammy Piper, Cindy Q. Yao, Janet A. Dunn, Paul C. Boutros, Robert C. Stein, OPTIMA Trial Management Group John M. S. Bartlett, Jane Bayani, Elizabeth N. Kornaga, Patrick Danaher, Cheryl Crozier, Tammy Piper, Cindy Q. Yao, Janet A. Dunn, Paul C. Boutros, Robert C.